Suzanne Shelley

Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.

Stockpiling excess inventory is no longer enough to respond to supply chain volatility.

Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.

Expanded use of data analytics can help to avoid disruptions, but the possibilities cannot be realized without sufficient investment and direct human involvement.

The option of using prefilled syringes for vaccinations is not (yet) available for all types of vaccines. Stakeholders are working to expand that option while also pursuing other non-traditional routes of administration.

Ongoing advances in technology and modeling techniques are helping to align all the objectives of both drug manufacturers and patients.